Abstract: In the metal iron golf club head (1), the rigidity of the medium sensitivity region (5) which is a region on the heel side and excluding the vicinity of the face center (3) is made lower than the rigidity of the low sensitivity region (4) so as to approximate the natural frequency of the metal iron golf club head to the natural frequency of the ball as well as to ensure the strength in the face portion (2).

Abstract: A door mirror structure is provided which can improve assembly workability of a door mirror. A cord is pulled out from a base end portion of a door mirror body. In an overhanging portion of a door mirror base, a slot is formed in place of a conventional cord insertion hole. Therefore, at a door mirror assembly line, the cord can easily be inserted into the slot from an arrow A direction. As a result, the assembly workability of the door mirror can be improved.

Abstract: The inventive golf club comprises a head of a metal having a face and a flexural range, defined in the face, where the quantity of flexure in a direction perpendicular to the face is at least 45% of the maximum quantity of vertical flexure of the face. The flexural range is arranged in coincidence with a hitting spot distribution range of a player in the face. Alternatively, a flexural range having a spring constant of at least 2 kN/mm and not more than 4 kN/mm is present in the face of the inventive golf club.

Abstract: An EC panel drive unit for a rear-view mirror comprising a timer circuit 2 in which a drive signal is output for a fixed period of time when either a colored state switch SW1 or a colorless state switch SW2 is in the ON position; a D-type flip-flop circuit 9 that sends different output signals, depending on whether the colored state switch SW1 is in the ON position or the colorless state switch SW2 is in the ON position, and a colored/colorless state switching circuit 6 which switches the polarity of DC voltage that is output from a lithium battery based on the output from the D-type flip-flop circuit 9 and then applies the voltage to input terminals Ta and Tb of the EC panel 7. A contact SW2-3 is installed between the two input terminals, Ta and Tb, of the EC panel 7 for providing a short circuit between the two terminals when the colorless state switch SW2 is turned to the ON position.

Abstract: A mirror assembly for a vehicle, the assembly being provided a mirror, a light assembly having a lens, a visor for accommodating the mirror and the light assembly, with the visor having a visor opening into which the lens is fitted, a connection element for movably connecting an end of the visor opening and an end of the lens, and a bias element for biasing the light assembly such that the visor opening is substantially closed with the lens.

Abstract: A door mirror structure is provided which can improve assembly workability of a door mirror. A cord is pulled out from a base end portion of a door mirror body. In an overhanging portion of a door mirror base, a slot is formed in place of a conventional cord insertion hole. Therefore, at a door mirror assembly line, the cord can easily be inserted into the slot from an arrow A direction. As a result, the assembly workability of the door mirror can be improved.

Abstract: In the metal iron golf club head (1), the rigidity of the medium sensitivity region (5) which is a region on the heel side and excluding the vicinity of the face center (3) is made lower than the rigidity of the low sensitivity region (4) so as to approximate the natural frequency of the metal iron golf club head to the natural frequency of the ball as well as to ensure the strength in the face portion (2).

Abstract: In the metal iron golf club head (1), the rigidity of the medium sensitivity region (5) which is a region on the heel side and excluding the vicinity of the face center (3) is made lower than the rigidity of the low sensitivity region (4) so as to approximate the natural frequency of the metal iron golf club head to the natural frequency of the ball as well as to ensure the strength in the face portion (2).

Abstract: Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.

Abstract: A compound of the formula ##STR1## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.

Abstract: Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.

Abstract: The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are independently hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-3 alkoxy, n-botoxy, i-botoxy, sec-butoxy, R.sup.7 R.sup.8 N-- (wherein R.sup.7 and R.sup.8 are independently hydrogen or C.sub.1-3 alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or --O(CH.sub.2).sub.l OR.sup.19 (wherein R.sup.19 is hydrogen or C.sub.1-3 alkyl, and l is 1,2 or 3); or when located at the ortho position to each other, R.sup.1 and R.sup.2, or R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH--; or when located at the ortho position to each other, R.sup.1 and R.sup.2 together form --OC(R.sup.15) (R.sup.16)O--(wherein R.sup.15 and R.sup.16 are independently hydrogen or C.sub.1-3 alkyl); Y is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --CH.dbd.CH-- or -- CH.dbd.CH--CH.sub.

Abstract: The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates.

Abstract: The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, sec-butoxy, R.sup.5 R.sup.6 N-- (wherein R.sup.5 and R.sup.6 are independently hydrogen or C.sub.1-3 alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or --O(CH.sub.2).sub.l OR.sup.15 (wherein R.sup.15 is hydrogen or C.sub.1-3 alkyl, and l is 1, 2 or 3); or when located at the ortho position to each other, R.sup.1 and R.sup.2 together form --CH.dbd.CH--CH.dbd.CH-- or methylene dioxy; Y is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --CH.dbd.CH-- or --CH.dbd.CH--CH.sub.2 --; Z is --Q--CH.sub.2 WCH.sub.2 --CO.sub.2 R.sup.12, ##STR2## (wherein Q is --C(O)--, --C(OR.sup.13).sub.2 -- or --CH(OH)--; W is --C(O)--, --C(OR.sup.13).sub.2 -- or --C(R.sup.11) (OH)--; R.sup.11 is hydrogen or C.sub.

Abstract: The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are independently hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-3 alkoxy, n-botoxy, i-botoxy, sec-butoxy, R.sup.7 R.sup.8 N-- (wherein R.sup.7 and R.sup.8 are independently hydrogen or C.sub.1-3 alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or --O(CH.sub.2).sub.l OR.sup.19 (wherein R.sup.19 is hydrogen or C.sub.1-3 alkyl, and l is 1,2 or 3); or when located at the ortho position to each other, R.sup.1 and R.sup.2, and R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH--; or when located at the ortho position to each other, R.sup.1 and R.sup.2 together form --OC(R.sup.15)(R.sup.16)O-- (wherein R.sup.15 and R.sup.16 are independently hydrogen or C.sub.1-3 alkyl); Y is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 CH.dbd.CH-- or --CH.dbd.CH-- CH.sub.

Abstract: The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates. The compounds are used as anti-hyperlipoproteinemic agents for example.

Abstract: Disclosed is a process for preparing a 3-hydroxy-7-mercaptopyrazolo[4,3-d]pyrimidine compound represented by the general formula (IX): ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group or a substituted phenyl group, which comprises:from a pyrazole compound represented by the general formula (III): ##STR2## wherein R.sup.1 is the same as defined above. Also disclosed are pyrazole compounds represented by the general formula (I): ##STR3## The compounds serve as intermediate for preparing the compound of the formula (IX).